Roth Capital Maintains Buy on CervoMed, Lowers Price Target to $11

CervoMed Inc. -4.96%

CervoMed Inc.

CRVO

3.83

-4.96%

Roth Capital analyst Boobalan Pachaiyappan maintains CervoMed (NASDAQ: CRVO) with a Buy and lowers the price target from $19 to $11.